TerminatedNot Applicable

Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer

Stopped: Lack of eligible patients

France2 participantsStarted 2024-02-19

Plain-language summary

This is an observational, single-centre study (RIPH3) for patients with rectal cancer soon to be treated with chemotherapy (+/- neo-adjuvant radio-chemotherapy) looking at the relationship between the composition of the gut microbiota before treatment and the tumour response after chemotherapy +/- radio-chemotherapy

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically proven stage II and III adenocarcinoma of the lower and middle rectum * Patient undergoing preoperative treatment with induction chemotherapy (Folfirinox) followed or not by radio-chemotherapy of the Cap50 type * Male or female patient aged 18 years or older * Normal weight, overweight or moderately obese (BMI between 18.5 and 34.9) * Patient residing in the Lille metropolitan area * Patient affiliated to a French social protection scheme * Patient having given his non-opposition Exclusion Criteria: * History of other concurrent cancers * Presence of an intestinal (internal or external) or external urinary diversion * Uncooperative patient for geographical, family, social or psychological reasons * Limited legal capacity or legal incapacity

What they're measuring

Gut microbiota description at T0

Timeframe: at baseline

histological response according to Ryan classification

Timeframe: after surgery, an average of 8 months after inclusion

Trial details

NCT IDNCT06181201

SponsorCentre Oscar Lambret

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10-08

View on ClinicalTrials.gov More Cancer of Rectum trials